ÂÜÀòÂÒÂ×

Petri Kouvonen is a seasoned professional in the biomedical field, currently serving as the Diabetic Foot Indication Manager at Bonalive Biomaterials since October 2021, with global responsibility for this indication. Prior to this role, Petri held the position of Senior R&D Scientist at Thermo Fisher Scientific from March 2017 to August 2021, leading the development of novel LC/MS-based applications in clinical microbiology and overseeing the Quality Control and Performance & Diagnostics teams. Previous experience includes serving as a Senior Researcher and Scientific Coordinator at the Turku Centre for Biotechnology, where Petri led clinical proteomics initiatives, and as a Postdoctoral Fellow at the Institute of Molecular Systems Biology, focusing on proteomic analysis of clinical tissue. Petri began the research career at the University of Turku, accumulating extensive experience in proteomics and mass spectrometry. Petri Kouvonen holds a Doctor of Philosophy (PhD) in Biochemistry from the University of Turku.